Clinical Trial Update: Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients [Phase 1, Phase 2]

View source ↗

Summary

Early-phase study assessing safety, tolerability, and immune response of the IMVAMUNE (MVA-BN) smallpox vaccine in HIV-infected individuals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• IMVAMUNE (MVA-BN) Smallpox Vaccine (Modified vaccinia Ankara (MVA-BN))

Snippet

Sponsor: Bavarian Nordic | Conditions: HIV Infections | Phase 1, Phase 2 | Status: COMPLETED